Clinical Trials
13
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:10
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1
10 (76.9%)Phase 2
3 (23.1%)A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
Phase 2
Not yet recruiting
- Conditions
- NPCHNSCCRecurrenceMetastasis
- Interventions
- Biological: IAE0972+DocetaxelBiological: IAE0972+GemcitabineBiological: IAE0972+TaxanesBiological: IAE0972+Capecitabine
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06719479
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
Phase 1
Recruiting
- Conditions
- Advanced Malignant NeoplasmAdvanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT06581419
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06504732
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06292208
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China
A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer
Phase 1
Not yet recruiting
- Conditions
- Bladder Cancer
- Interventions
- Combination Product: IAP0971＋BCG
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 236
- Registration Number
- NCT06255964
- Prev
- 1
- 2
- 3
- Next
News
No news found